KEI

@KEI_DC

Knowledge Ecology International is a non-profit group that advocates for access to knowledge & access to affordable medicines.

Vrijeme pridruživanja: kolovoz 2013.

Tweetovi

Blokirali ste korisnika/cu @KEI_DC

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @KEI_DC

  1. Prikvačeni tweet
    30. svi 2017.
    Poništi
  2. proslijedio/la je Tweet
    24. svi 2019.
    , , i još njih 7
    Poništi
  3. proslijedio/la je Tweet

    “We want to open the black box” – Gaelle Krikorian of on the need for a strong

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet

    Countries trying to block begin negotiations today complaining bitterly about WHO having published a conference paper with country positions listed. They don't like being accountable for terrible positions.

    Poništi
  5. proslijedio/la je Tweet

    WHA72 – Open Letter to Delegates on Transparency Resolution Negotiations

    Poništi
  6. proslijedio/la je Tweet
    22. svi 2019.

    . published the Conference Paper (A72/A/CONF./2) on the - Germany, the UK, and other governments have sought to inflict a death by a thousand cuts to kill the transparency resolution (in the form of 110 brackets).

    , , i još njih 5
    Poništi
  7. proslijedio/la je Tweet
    Poništi
  8. proslijedio/la je Tweet
    Poništi
  9. proslijedio/la je Tweet

    For delegates claiming R&D outlays and government R&D subsidies are trade secrets, check out these SEC discloses.

    Poništi
  10. proslijedio/la je Tweet

    📣HAPPENING NOW at the : governments have a historic opportunity to put lives over profits and make medicines more affordable. RT to tell governments to support a clear, bold !

    Poništi
  11. proslijedio/la je Tweet
    20. svi 2019.

    . Italy and 11 co-sponsors introduce transparency resolution text to

    , , i još njih 5
    Poništi
  12. proslijedio/la je Tweet
    20. svi 2019.
    Poništi
  13. proslijedio/la je Tweet
    20. svi 2019.

    James Love from providing some great insights into the conflicting info on the price of clinical trials (from 10 mill - to 1 bill!!) adding further strength to the arguement for increasing around clinical trials

    Poništi
  14. 20. svi 2019.

    Anban Pillay of South Africa: By making them agree to secrecy on drug pricing agreements, pharma’s plan is to make every country/entity feel like they’re getting the best price compared to everyone else.

    Poništi
  15. proslijedio/la je Tweet
    20. svi 2019.

    Dr Nikolaos Raptis, Adviser to MoH Greece: non disclosure agreements (NDAs) in Managed Entry Agreements are good for Pharma and very bad for patients and Govts!

    Poništi
  16. proslijedio/la je Tweet
    20. svi 2019.

    Baskozos of Greece: ´We welcome . 🇬🇷 remains committed to international cooperation to improve

    Poništi
  17. 20. svi 2019.

    Spanish Secretary of Health Dr. Faustino Blanco says that treatment prices need to be related to costs of their development and production (and we therefore need on that information) side event

    Poništi
  18. proslijedio/la je Tweet
    20. svi 2019.

    Minister of Health of Portugal says transparency is key for good governance & sustainability of efforts & recognizes key role of

    Poništi
  19. 20. svi 2019.

    Prof. Kwon cites model as alternative incentive system from current patent monopoly system for increasing access to medicines at side event at

    Poništi
  20. proslijedio/la je Tweet
    20. svi 2019.

    High prices can’t be justified by cost of if the information is not there to review - strong opening by undersecretary of state for health debate opened up at

    Poništi
  21. proslijedio/la je Tweet
    20. svi 2019.

    Italian Health Ministry representative: is the solution to information & power asymmetries in systems

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·